NUP62 and early-onset autosomal dominant Alzheimer disease: HDPSCs possess proliferative, multilineage differentiation and immunomodulatory abilities.7,9 Numerous studies have showed their potential for treating age-related diseases, such as osteoarthritis, Parkinson’s disease, and Alzheimer’s disease.8,54 However, HDPSCs exhibit a decline in both proliferative capacity and regenerative efficiency as age increases, which involve different molecular mechanisms.10,11 Targeting NUP62 could enhance the regenerative efficiency of O-HDPSCs, potentially supporting the clinical application of HDPSCs in regenerative medicine.